Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024)
Alto Neuroscience (ANRO) posted Receivables - Other of -$8000.0 for Q1 2024, down 200.0% sequentially from $8000.0 in Q4 2023, and down 121.62% YoY from $37000.0 in Q2 2023.
Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024) Analysis & Trends
Alto Neuroscience has reported Receivables - Other for 2 years, with the latest figure at -$8000.0 in Q1 2024.
- Quarterly Receivables - Other fell 121.62% year-over-year to -$8000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$333000.0 (changed N/A YoY) and the FY2023 annual result came in at $8000.0, changed N/A from the prior year.
- Receivables - Other eased to -$8000.0 in Q1 2024 per ANRO's latest filing, from $8000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $37000.0 in Q1 2023 and troughed at -$295000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Mar 31, 2023 | 37,000.00 |